October 2023 in “Microorganisms” Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
5 citations
,
July 2007 in “PubMed” An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.
100 citations
,
November 2021 in “Cell Research” Cepharanthine and Trifluoperazine are effective against SARS-CoV-2.
7 citations
,
July 2007 in “Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy” The medication lopinavir-ritonavir may cause severe hair loss.
August 2018 in “bioRxiv (Cold Spring Harbor Laboratory)” Existing drugs, including a blood pressure medication, show promise as new treatments for influenza.
1 citations
,
November 2011 in “Journal of AIDS & Clinical Research” Raltegravir may cause hair loss in some patients.
42 citations
,
January 2019 in “Frontiers in Immunology” A blood pressure drug, diltiazem, may also help treat influenza.
November 2012 in “Journal of the International AIDS Society” Antiretrovirals can affect finasteride's effectiveness, so dose adjustments may be needed for men on HIV treatment.
1 citations
,
December 2004 in “Hepatology” Tenofovir is more effective than adefovir for resistant hepatitis B, Fibroscan is good for assessing liver damage, regulatory T cells may help hepatitis C persist, and other insights into liver health and disease were found.
5 citations
,
December 2022 in “Annals Academy of Medicine Singapore” Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
1 citations
,
June 2020 in “Unisa Institutional Repository (University of South Africa)” Low power red laser with efavirenz can reduce HIV-1 infection to undetectable levels and improve diagnosis.
17 citations
,
February 2011 in “Expert Opinion on Drug Safety” Manage side effects of hepatitis C treatment with dose changes and medications, which may improve patient adherence and treatment success.
36 citations
,
January 1993 in “Gut” High-dose interferon is effective for chronic hepatitis C but often causes flu-like symptoms.
32 citations
,
October 2004 in “Pharmacotherapy” Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
17 citations
,
January 1993 in “Journal of Gastroenterology and Hepatology” Interferon α‐2b can temporarily reduce hepatitis C virus and normalize liver enzyme levels.
10 citations
,
September 2014 in “European Journal of Dermatology” A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.
17 citations
,
August 2002 in “AIDS” Indinavir and ritonavir therapy can cause reversible hair loss.
27 citations
,
April 2005 in “Journal of Chemotherapy” Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.
52 citations
,
October 2010 in “Antiviral Therapy” New treatments for Hepatitis C show promise but need more research to confirm their safety and effectiveness for clinical use.
November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Five FDA-approved drugs may help block COVID-19 virus entry.
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
5 citations
,
December 2015 in “PubMed” Some gonadal hormone drugs can block filovirus entry into cells.
176 citations
,
June 2016 in “PLoS ONE” Nucleic acid polymers can enhance antiviral responses and improve treatment outcomes for chronic hepatitis B.
August 2025 in “BMC Pharmacology and Toxicology” The LTF gene may help predict and manage nonspecific orbital inflammation.
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
17 citations
,
January 2011 in “The Korean Journal of Hepatology” Vogt-Koyanagi-Harada disease can develop during interferon therapy for chronic hepatitis C.
20 citations
,
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Six existing drugs may help block virus entry in COVID-19.
June 2016 in “Afro-Egyptian Journal of Infectious and Endemic Diseases” Most patients on this hepatitis C treatment experienced skin issues, especially hair loss.
Lamivudine might reverse hair graying and needs more research for potential treatments.